- Previous Close
16.60 - Open
16.60 - Bid 16.20 x --
- Ask 16.60 x --
- Day's Range
16.50 - 16.80 - 52 Week Range
5.50 - 18.40 - Volume
2,141 - Avg. Volume
6,018 - Market Cap (intraday)
362.809M - Beta (5Y Monthly) 0.15
- PE Ratio (TTM)
-- - EPS (TTM)
-2.77 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.00
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular. The company was incorporated in 2010 and is based in Umeå, Sweden.
www.lipum.seRecent News: LIPUM.ST
View MorePerformance Overview: LIPUM.ST
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIPUM.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIPUM.ST
View MoreValuation Measures
Market Cap
352.13M
Enterprise Value
351.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
7.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.90%
Return on Equity (ttm)
-126.99%
Revenue (ttm)
53k
Net Income Avi to Common (ttm)
-39.24M
Diluted EPS (ttm)
-2.77
Balance Sheet and Cash Flow
Total Cash (mrq)
12.87M
Total Debt/Equity (mrq)
24.67%
Levered Free Cash Flow (ttm)
-73.22M